Filtered By:
Specialty: Pharmaceuticals
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 890 results found since Jan 2013.
Medication errors associated with direct-acting oral anticoagulants: analysis of data from national pharmacovigilance and local incidents reporting databases
ConclusionsThis observational study demonstrates the nature of DOAC related medication errors in clinical practice. Developing risk prevention and reduction strategies using the expertise of clinical pharmacists are imperative in promoting patient safety associated with DOAC use.
Source: Journal of Pharmaceutical Policy and Practice - October 1, 2021 Category: Pharmaceuticals Source Type: research
FDA Approves Abbott's Amplatzer ™ Talisman™ System for PFO Closure in People at Risk of Recurrent Stroke
- Talisman system builds on the minimally invasive Amplatzer PFO Occluder, the world's leading patent foramen ovale (PFO) closure device that has been used to treat more than 180,000 patients worldwide
Source: Abbott.com - September 29, 2021 Category: Pharmaceuticals Source Type: news
Medtronic Receives CE Mark Approval for Radial Artery Access Portfolio
Portfolio Features First Catheter Specifically Designed to Allow Neurointerventionalists Radial Artery Access, Delivers Advantages to Patients Treated for Stroke, Brain Aneurysms, Other Neurovascular Conditions
Now Available in the United Kingdom, Italy... Devices, Interventional, Regulatory Medtronic, radial artery access, Rist 079 Radial
Source: HSMN NewsFeed - September 28, 2021 Category: Pharmaceuticals Source Type: news
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news
NIH scientists build a cellular blueprint of multiple sclerosis lesions
Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms of the disease. Using brain tissue from humans, researchers at the National Institutes of Health's National Institute of Neurological Disorders and Stroke (NINDS) built a detailed cellular map of chronic MS lesions, identifying genes that play a critical role in lesion repair and revealing potential new therapeutic targets for progressive MS.
Source: World Pharma News - September 10, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Outcomes for Acute Stroke Better With Mobile Stroke Units
WEDNESDAY, Sept. 8, 2021 -- For patients within 4.5 hours after onset of acute stroke symptoms who are eligible for tissue plasminogen activator (t-PA), outcomes are better with treatment with mobile stroke units (MSUs) than standard management by...
Source: Drugs.com - Pharma News - September 8, 2021 Category: Pharmaceuticals Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
MicroTransponder(R) Receives FDA Approval for Breakthrough Device Benefiting Stroke Survivors
The first-of-its-kind Vivistim® Paired Vagus Nerve Stimulation (VNS) System significantly improves upper limb rehabilitation therapy
DALLAS, Aug. 31, 2021 -- (Healthcare Sales & Marketing Network) -- MicroTransponder, Inc. today announced United St... Devices, Neurology, FDA MicroTransponder, Vivistim Paired VNS System, Vagus Nerve Stimulation, stroke
Source: HSMN NewsFeed - August 31, 2021 Category: Pharmaceuticals Source Type: news
Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Late-Breaking Data Shows Abbott's Amplatzer ™ Amulet™ Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman‡ Device for People With Atrial Fibrillation at Risk of Stroke
- New data presented at ESC Congress 2021 and simultaneously published in Circulation show Amulet Occluder was superior in left atrial appendage (LAA) closure and noninferior on safety and effectiveness endpoints compared to Watchman device
Source: Abbott.com - August 30, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves First Nerve-Stimulation Device to Aid Stroke Recovery
FRIDAY, Aug. 27, 2021 -- A first-of-its-kind nerve stimulation treatment for people who have difficulty moving their arms after a stroke has been approved by the U.S. Food and Drug Administration.
The Vivistim System is a prescription therapy for...
Source: Drugs.com - Pharma News - August 27, 2021 Category: Pharmaceuticals Source Type: news
Covid Infection Has ‘Much Higher’ Risk Of Blood Clots Than Vaccines Do, Study Finds
While there is an increased risk of stroke after the first Pfizer shot and a higher change of blood clotting following AstraZeneca, a Covid-19 infection comes with at least ten times higher risk, research found.
Source: Forbes.com Healthcare News - August 27, 2021 Category: Pharmaceuticals Authors: Robert Hart, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news Editors' Pick editors-pick Coronavirus Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
